Selskabets formål er udvikling og fremstilling af samt handel med lægemidler og hermed beslægtede varer.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 1.1 mia. | 12.2 mio. | 581.3 mio. | 368.3 mio. | 68 | |
CVR: 16406899
Secondary names: NYCOMED DANMARK A/S, DAK LABORATORIES A/S, NYCOMED DAK A/S
Previous names: DAK-LABORATORIET A/S, NYCOMED DAK A/S, NYCOMED DANMARK A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 27394019
CVR 55541817
CVR 42541877
CVR 45267024
CVR 43401548
The financial health of TAKEDA PHARMA A/S appears to be fluctuating, with a notable decline in profitability over the past few years. Revenue peaked at 1,939,231,000 DKK in 2021 but has since decreased to 1,102,419,000 DKK in 2025, while profit has significantly dropped from 667,744,000 DKK in 2021 to just 12,162,000 DKK in 2025. Despite a positive equity trend, increasing from 81,238,000 DKK in 2022 to 368,294,000 DKK in 2025, the company's profit margins are concerning. Positioned within the pharmaceutical wholesale industry, its recent performance raises questions about operational efficiency and market competitiveness.
AI-generated summary
Christian Ramskov joined the board
Koki Sato joined the board
Koki Sato joined as director
Christian Ramskov left the board
Koki Sato left the board
Georgios Faidon Kalomoiris left as director
Georgios Faidon Kalomoiris joined as director
Christian Ramskov left as ADM. DIR.
companydata.dk